NCT05775159 2026-04-17
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
Phase 2 Recruiting
Clinical Trials
15 trialsNCT07535840 2026-04-17
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
Tongji Hospital
Phase NA Not yet recruiting
NCT07537946 2026-04-17
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
Tongji Hospital
Phase 3 Not yet recruiting
NCT07530445 2026-04-15
Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT06880523 2026-04-14
SLIDE-HCC
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT04745988 2026-04-09
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer
National Cancer Center Hospital East
Phase 2 Active not recruiting
NCT07518706 2026-04-09
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05301842 2026-04-07
EMERALD-3
AstraZeneca
Phase 3 Active not recruiting
NCT04039607 2026-04-06
CheckMate 9DW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT07495579 2026-03-27
REVIVE
Asan Medical Center
Phase 2 Not yet recruiting
NCT05024214 2026-03-25
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
3D Medicines
Phase 1/2 Recruiting
NCT06858813 2026-03-25
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
AbbVie
Phase 1 Recruiting
NCT07493668 2026-03-25
FLEX-HCC
CHA University
Phase 2 Not yet recruiting
NCT04008797 2026-03-24
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting
NCT05319730 2026-03-20
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting